Camurus AB (publ)

BATS-CHIXE:CAMXS Stock Report

Market Cap: SEK 33.3b

Camurus Valuation

Is CAMXS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAMXS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: CAMXS (SEK558) is trading below our estimate of fair value (SEK1831.51)

Significantly Below Fair Value: CAMXS is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAMXS?

Key metric: As CAMXS is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for CAMXS. This is calculated by dividing CAMXS's market cap by their current earnings.
What is CAMXS's PE Ratio?
PE Ratio125.3x
EarningsSEK 266.21m
Market CapSEK 33.34b

Price to Earnings Ratio vs Peers

How does CAMXS's PE Ratio compare to its peers?

The above table shows the PE ratio for CAMXS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average36.3x
HIK Hikma Pharmaceuticals
19.4x12.2%UK£4.4b
ANCR Animalcare Group
31.1x5.3%UK£143.7m
GSK GSK
21.8x23.2%UK£54.7b
EAH ECO Animal Health Group
73.1x39.2%UK£48.1m
CAMXS Camurus
125.3x83.1%SEK 33.3b

Price-To-Earnings vs Peers: CAMXS is expensive based on its Price-To-Earnings Ratio (125.3x) compared to the peer average (36.3x).

Price to Earnings Ratio vs Industry

How does CAMXS's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

1 CompanyPrice / EarningsEstimated GrowthMarket Cap
No. of Companies11PE01632486480+
1 CompanyEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: CAMXS is expensive based on its Price-To-Earnings Ratio (125.3x) compared to the European Pharmaceuticals industry average (19.5x).

Price to Earnings Ratio vs Fair Ratio

What is CAMXS's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAMXS PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio125.3x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate CAMXS's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAMXS forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentSEK 558.00
SEK 745.00
+33.5%
2.8%SEK 768.00SEK 710.00n/a6
Dec ’25n/a
SEK 745.00
0%
2.8%SEK 768.00SEK 710.00n/a6
Nov ’25n/a
SEK 753.33
0%
1.7%SEK 773.00SEK 730.00n/a6
Oct ’25n/a
SEK 742.67
0%
2.8%SEK 770.00SEK 710.00n/a6
Sep ’25SEK 703.25
SEK 742.67
+5.6%
2.8%SEK 770.00SEK 710.00n/a6
Aug ’25n/a
SEK 742.67
0%
2.8%SEK 770.00SEK 710.00n/a6
Jul ’25n/a
SEK 621.50
0%
9.4%SEK 690.00SEK 500.00n/a6
Jun ’25n/a
SEK 612.33
0%
12.7%SEK 690.00SEK 445.00n/a6
May ’25n/a
SEK 577.17
0%
14.4%SEK 690.00SEK 445.00n/a6
Apr ’25n/a
SEK 577.17
0%
14.4%SEK 690.00SEK 445.00n/a6
Mar ’25SEK 455.60
SEK 573.00
+25.8%
15.7%SEK 690.00SEK 420.00n/a6
Feb ’25SEK 507.25
SEK 549.83
+8.4%
20.8%SEK 690.00SEK 420.00n/a6
Jan ’25n/a
SEK 508.00
0%
19.8%SEK 650.00SEK 420.00n/a6
Dec ’24n/a
SEK 471.33
0%
17.3%SEK 650.00SEK 420.00n/a6
Nov ’24n/a
SEK 351.33
0%
6.7%SEK 380.00SEK 320.00n/a6
Oct ’24n/a
SEK 320.50
0%
17.4%SEK 380.00SEK 205.00n/a6
Sep ’24n/a
SEK 320.50
0%
17.4%SEK 380.00SEK 205.00SEK 703.256
Aug ’24n/a
SEK 320.50
0%
17.4%SEK 380.00SEK 205.00n/a6
Jul ’24n/a
SEK 298.17
0%
14.4%SEK 332.00SEK 205.00n/a6
Jun ’24SEK 290.80
SEK 298.17
+2.5%
14.4%SEK 332.00SEK 205.00n/a6
May ’24n/a
SEK 284.67
0%
14.1%SEK 320.00SEK 205.00n/a6
Apr ’24SEK 210.80
SEK 284.67
+35.0%
14.1%SEK 320.00SEK 205.00n/a6
Mar ’24SEK 224.20
SEK 284.67
+27.0%
14.1%SEK 320.00SEK 205.00SEK 455.606
Feb ’24n/a
SEK 310.00
0%
5.5%SEK 330.00SEK 280.00SEK 507.255
Jan ’24n/a
SEK 305.00
0%
5.1%SEK 320.00SEK 280.00n/a4
Dec ’23SEK 265.40
SEK 305.00
+14.9%
5.1%SEK 320.00SEK 280.00n/a4

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 13:03
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Camurus AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Oscar Haffen LammBryan Garnier & Co
Alexandru CogutBryan Garnier & Co
Kristofer Liljeberg-SvenssonCarnegie Investment Bank AB